Ketotifen treatment for children with functional dyspepsia and duodenal eosinophilia
Official title: Double-blind, Placebo-controlled, Cross-over Trial of Ketotifen in Children and Adolescents With Functional Dyspepsia in Association With Duodenal Eosinophilia
Run by Children's Mercy Hospital Kansas City · NCT02484248 · Data updated 2026-11-12
This study is testing if ketotifen can help children aged 8 to 17 with stomach issues and high eosinophils feel better when other treatments haven't worked.
Quick facts
| Phase | Phase 3 |
|---|---|
| Study type | Interventional |
| Ages | 8 Years to 17 Years |
| Sex | All |
| Enrollment | 40 (estimated) |
| Sponsor | Children's Mercy Hospital Kansas City Academic / other |
| Locations | 1 site (Kansas City, Missouri) |
| Status | Recruiting |
| Started | August 2015 |
| Main results expected | April 1, 2027 |
| Study ends | April 1, 2027 |
| Registry record updated | January 9, 2026 |
| Trial ID | NCT02484248 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are children aged 8 to 17 with a diagnosis of functional dyspepsia and evidence of duodenal eosinophilia who have not adequately responded to acid-reduction therapy.
✕Probably not a fit
Patients who have previously been treated with ketotifen or have certain chronic medical conditions may not benefit from this study.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This clinical trial evaluates the effectiveness of ketotifen, a mast cell stabilizer, in treating children aged 8 to 17 who suffer from functional dyspepsia associated with duodenal eosinophilia. The study is designed as a double-blind, placebo-controlled, cross-over trial, where participants will receive either ketotifen or a placebo in two phases. The primary goal is to assess the symptomatic response to ketotifen compared to placebo in children who have not adequately responded to standard acid-reduction therapy. Participants will undergo multiple clinic visits and phone interviews throughout the study duration to monitor their symptoms and overall health.
Why it matters
Potential benefit: If successful, this treatment could provide significant relief for children suffering from functional dyspepsia who have not responded to conventional therapies.
How similar studies have gone: While there have been no prior studies specifically on ketotifen for functional dyspepsia, mast cell stabilizers have shown benefits in related conditions, suggesting potential for success.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. between the ages of 8 and 17 years, inclusive 2. abdominal pain of at least 8 weeks duration and fulfilling symptom-based criteria for functional dyspepsia(5); 3. previous endoscopy with biopsies demonstrating \>20 eosinophils/high powered field on duodenal mucosal biopsies; 4. previous treatment with acid-reduction therapy and montelukast with a level 3 (as defined below)or lesser response; 5. evidence of written parental permission (consent) and subject assent; 6. Negative pregnancy screening for females of child bearing potential. Exclusion Criteria: 1. previous treatment with ketotifen; 2. treatment with oral corticosteroids or oral cromolyn sodium in the 6 months prior to enrollment; 3. any prior history of diabetes mellitus, cancer, chronic cardiac disease, respiratory disease, or renal disease requiring routine medical care; 4. Pregnant/planning to become pregnant; 5. Post-menarche females unwilling to use highly-efficacious contraception to prevent pregnancy; 6. Epilepsy or history of seizures; 7. Liver disease or elevation of liver enzymes; 8. Use of oral hypoglycemic medications, antipsychotics, benzodiazepines, tricyclic antidepressants, barbiturates, or opioids; 9. Allergy to ketotifen or other products in capsule 10. Refusal of Urine pregnancy test in post-menarchal females.
Where it's running
-
The Children's Mercy Hospital
Kansas City, Missouri, United States Recruiting
Study contacts
- Principal investigator: Craig A Friesen, MD — Children's Mercy Hospital Kansas City
- Study coordinator: Craig A Friesen, M.D.
- Email: cfriesen@cmh.edu
- Phone: 816-234-3066
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Low-FODMAP Diet vs Standard Dietary Advice for Functional Dyspepsia
This study tests whether a low-FODMAP diet helps adults with functional dyspepsia compared with standard dietary advice.
-
Pain Reprocessing Therapy for Functional Dyspepsia
A small pilot test to see if a psychological therapy that uses exposure techniques can lessen digestive symptoms and help daily functioning in people with functional dyspepsia.
-
Identifying Signatures of Gut Interoception in Functional Dyspepsia and Anorexia Nervosa
This study tests how the gut-brain connection works in people with functional dyspepsia or anorexia nervosa using brain imaging.
-
Prevalence and possible role of non-H. pylori Helicobacter species in gastric conditions and cancers
Researchers will test stomach tissue from people with functional dyspeasia, various gastritis conditions, gastric cancer, and bariatric patients to see if non-H. pylori Helicobacter species are present.
-
Liver Fat and Scarring in People Suspected of Non-Celiac Wheat Sensitivity
This study looks to see if people with non-celiac wheat sensitivity have liver fat or fibrosis and how this relates to IBS/FD and celiac disease.
-
Prevalence of Functional Dyspepsia in a Rural Community in Bangladesh
This study tests how common functional dyspepsia is in a rural Bangladeshi community among adults who live there.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.